RESUMO
Treatment of central precocious puberty (CPP) is the administration of GnRH analogs. Metabolic syndrome comprised metabolic disturbances that confer increased risk of (CVD) diabetes mellitus (DM) and cardiovascular disease. This study is a longitudinal prospective study in pediatric endocrinology clinic. 30 non-obese children with idiopathic CPP were involved. Total body weight, height, blood pressure, BMI and waist circumference of the patients along with their triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), fasting plasma sugar (FPS) were evaluated at the beginning and during 3 and 6 months GnRH analog therapy. All of the patients involved in this study were female with age 9.5±1.02 years. Waist circumference, weight and BMI were 69.3 cm, 37.21 kg, and 19.13 kg/cm(2) before therapy and 72.25 cm, 40.11 kg, and 19.54 kg/m(2) 6 months after therapy respectively. Mean systolic and diastolic blood pressure of the patients before therapy was 96.83 mmHg, 66mmHg and after 6 months therapy was 98.66 mmHg, 89.63 mmHg respectively. Mean TG, LDL, HDL and FPS were 90.06 mg/dl, 91.6 mg/dl, 43.7 mg/dl and 89.6 mg/dl before therapy and 96.4 mg/dl, 93.1 mg/dl, 44.7 mg/dl and 91.36 after 6 months therapy respectively. GnRH analog therapy doesn't cause metabolic syndrome after 3 and 6 month therapy but it may cause hyperlipidemia and central obesity.
Assuntos
Hormônio Liberador de Gonadotropina/efeitos adversos , Hiperlipidemias/induzido quimicamente , Síndrome Metabólica/induzido quimicamente , Obesidade Abdominal/induzido quimicamente , Puberdade Precoce/tratamento farmacológico , Pamoato de Triptorrelina/efeitos adversos , Biomarcadores/sangue , Glicemia/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Estatura/efeitos dos fármacos , Índice de Massa Corporal , Peso Corporal/efeitos dos fármacos , Criança , Feminino , Hormônio Liberador de Gonadotropina/análogos & derivados , Humanos , Hiperlipidemias/sangue , Hiperlipidemias/diagnóstico , Hiperlipidemias/fisiopatologia , Lipídeos/sangue , Estudos Longitudinais , Síndrome Metabólica/sangue , Síndrome Metabólica/diagnóstico , Síndrome Metabólica/fisiopatologia , Obesidade Abdominal/sangue , Obesidade Abdominal/diagnóstico , Obesidade Abdominal/fisiopatologia , Estudos Prospectivos , Puberdade Precoce/sangue , Puberdade Precoce/diagnóstico , Puberdade Precoce/fisiopatologia , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Pamoato de Triptorrelina/análogos & derivados , Circunferência da CinturaRESUMO
We selected 92 subjects (46 females and 46 males), aged 10-15 years, from the Haematology and Endocrine Clinic of Shiraz University, Iran. Forty-six were beta thalassaemia patients (beta-Th) with short stature, 23 had idiopathic short stature (ISS) and 23 were healthy children with a standing height between the 10th and 95th percentile. Growth hormone (GH) secretion was normal in 23 beta-Th patients and reduced in the remaining 23 patients. A low insulin growth factor I (IGF-I) was found in 73.9% of beta-Th patients with GH deficiency, 56.5% of beta-Th patients with normal GH secretion to stimulation test and 8.7% of children with ISS. The reduced IGF-I concentration in beta-Th patients with normal GH secretion may be explained by partial insensitivity to GH (GHIS), neurosecretory dysfunction, low bioactive GH or increased proportion of circulating, non-22-kDa GH isoform. The possibility of GHIS in beta-Th patients with short stature indicates that higher doses of rechGH may be required to obtain an improvement in growth velocity in beta-Th patients.